BIND Therapeutics, which is developing a new class of targeted and programmable therapeutics called Accurins™, has secured its second big pharma partner. The company has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering® platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. BIND formed a similar collaboration with Amgen in January 2013 and will use the payments it receives from the two partnerships to fund a Phase II clinical programme for its lead drug candidate BIND-014 in multiple solid tumours.